On Apr. 24, 2020, BioSig Technologies announced that subsidiary ViralClear had submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its phase II clinical trial with merimepodib as a treatment for COVID-19.

The study was a randomized, placebo-controlled trial to evaluate the efficacy and safety of Merimepodib in patients with COVID-19.

The placebo-controlled Phase II clinical trial called for 20 planned patients from three Mayo Clinic sites: Rochester, MN; Scottsdale, AZ; and Jacksonville, FL. Data from the Phase II trial was expected within three months of the commencement of the trial.